Skip to main content
OpenTrials
Completed

NCT Number: NCT05141370

Assessment of a Femtosecond Laser to Perform Capsulorhexis During Cataract Surgery

This study is a Pre-market first-in-man clinical investigation to validate performance of a hand-held femtosecond laser named CATSYS.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Institut Opthalmologique Sourdille Atlantique

Saint-Herblain, 44800, France

About this study

Interventional, prospective, longitudinal (follow-up: 30 ± 10 days), single-arm, single center, open trial. The "first-in-man" character of this investigation relies on the ergonomics of CATSYS (handpiece), and not on the laser technique, which is similar to other FLACS.

The purpose of the clinical investigation is to document the compliance of the investigational medical device with the general requirements of performance, safety and clinical benefit, in order to complete existing data and obtaining CE-mark for CATSYS.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with cataract requiring surgery according to current guidelines;
  • Eligible to lens removal by phacoemulsification and replacement by a prosthetic lens under local anesthesia;
  • Who have been informed and gave informed consent to participate in the study.

Exclusion criteria

  • Eye with an anterior chamber depth < 2.5 mm or > 3.8 mm;
  • Corneal disease or pathology that precludes applanation of the cornea or transmission of laser wavelength or distortion of laser light;
  • Eye with a poorly dilating pupil or other defect of the pupil that prevents the iris from adequate retraction peripherally;
  • Patient with residual, recurrent, active ocular or eyelid disease, including any corneal abnormality (for example, recurrent corneal erosion, severe basement membrane disease) in either eye;
  • History of steroid-responsive rise in IOP, glaucoma, or preoperative IOP>21 mm Hg in either eye;
  • Lens/zonular instability such as, but not restricted to, Marfan's Syndrome, pseudoexfoliation syndrome, etc;
  • Previous intraocular or corneal surgery of any kind, including any type of surgery for either refractive or therapeutic purposes in either eye;
  • Any recent penetrating incision of the eyeball;
  • Tilt of lens > 7;
  • Presence of any obstacle that may interfere with the stabilization of the device on the limbus: pterygium, limbic tumor, etc;
  • Pregnant or lactating woman;
  • Patient with any contra-indication to neosynephrine, tropicamide and oxybuprocaïne;
  • Patient presenting any contraindications to cataract surgery under local anesthesia (ex: allergy to anesthetic drops; neurodegenerative disease; schizophrenia; severe anxiety; etc.);
  • Patient who participates to another clinical trial (except observational studies), or in the exclusion period of another clinical trial;
  • Patient under guardianship, trusteeship or deprived of liberty;
  • Patient not affiliated to the French social security system;
  • Patient unable to participate in the study for psychiatric, cognitive or linguistic reasons.

Treatment and study plan

cataract surgery with CATSYS

Device

patient diagnosed with cataract requiring surgery will have an anterior capsulorhexis with CATSYS

Primary outcomes

  1. Continuity of the capsulorhexis (success / failure)

    Time frame: During surgery

    Success achieved if:

    • the anterior capsule is completely cut (rhexis is free floating or easy to remove)
    • AND there are no peripheric tears that can generate the rupture of the capsule at the end of rhexis removal.

Secondary outcomes

  1. Adverse device effects

    Time frame: 3 to 5 days after surgery

    Collection of adverse device effects by the investigator on the retina, on the cornea, on the posterior capsula and other adverse device events

  2. Adverse events

    Time frame: 3 to 5 days post-surgery;

    Collection by the investigator of other adverse events

  3. Ocular adverse events

    Time frame: 30 ± 10 days post-surgery.

    Collection by the investigator of ocular adverse events

Sponsors and collaborators

Lead sponsor

Ilasis Laser

Industry

Registry information

Official study title

Assessment of a Hand-held Femtosecond Laser to Perform Anterior Capsulorhexis During Cataract Surgery

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Dec 2, 2021
Registry last updated
Oct 2, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.